Announcements Trials
Browse Landscape

Status

Unknown 3Recruiting 3Completed 3Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 40Observational 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

TAS 102 1Colorectal Neoplasms 1Colorectal Adenocarcinoma 1

Interventions

Blood Specimen Collection 85Surveys and Questionnaires 83Surgical Procedures, Operative 44Drug Therapy 32Radiotherapy 27Biopsy 26Amplified Fragment Length Polymorphism Analysis 24Neoadjuvant Therapy 23Immunohistochemistry 22Gene Expression Profiling 21Bevacizumab 19Data Collection 18Immunotherapy 17Ultrasonography 16Positron Emission Tomography Computed Tomography 16Magnetic Resonance Spectroscopy 16Liquid Biopsy 16pembrolizumab 15Nivolumab 15Watchful Waiting 14Radiosurgery 14Observation 14Microarray Analysis 14Magnetic Resonance Imaging 14Interviews as Topic 14Immune Checkpoint Inhibitors 13Colonoscopy 13Capecitabine 13Polymerase Chain Reaction 12Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Observational × HMPL-013 × Clear all
NCT05993702 2023-08-15

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

China Medical University, China

Unknown
45 enrolled
Gastrointestinal

TAS 102

NCT05635149 2022-12-02

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Unknown
100 enrolled
Gastrointestinal

Colorectal Adenocarcinoma

NCT04431791 2020-06-16

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Peking University

Unknown
268 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡